SGP - SpyGlass Pharma, Inc. Common Stock Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

SGP

SPYGLASS PHARMA, INC. COMMON STOCK

NASDAQ

$29.08

▼ DOWN 0.85% (-0.25)

KEY STATISTICS

Market Cap$972.24 M

52w High$32.44

52w Low$17.06

Dividend Yield—

Frequency—

P/E-4.54

Volume613.83K

Shares Out.33.43M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Patrick Mooney

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 6, 2026

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$39.00

Target Low$39.00

Target Median$39.00

Target Consensus$39.00

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.—

NOV

THU

PRICE

$29.08 ▼ DOWN 0.85% (−$0.25)

About SpyGlass Pharma, Inc. Common Stock

http://www.spyglasspharma.com ↗

SpyGlass Pharma, Inc., founded in 2019 in Aliso Viejo, CA, develops treatments for chronic eye conditions, with its lead product, BIM-IOL System, implanted during cataract surgery to lower intraocular pressure in glaucoma and ocular hypertension p...

INDUSTRY

Biotechnology

A PRODUCT SPYGLASS PHARMA, INC. COMMON STOCK IS KNOWN FOR

BIM-IOL System

SpyGlass Pharma's BIM-IOL System, in Phase III trials, is an intraocular lens with drug pads that delivers sustained bimatoprost release during cataract surgery, aiming for up to three years of glaucoma management and reducing daily eye drop use.